Abbott Readying Vildagliptin ER In India Amid Price Competition

 
• By Anju Ghangurde

Abbott is developing an extended release version of vildagliptin in India, adding a new dimension to the market dynamics for the DPP-4 inhibitor, which has seen a key patent expire. Sustained release vildagliptin products from Wockhardt and Synokem also appear to be in the works.

Leadership
Abbott's Extended Release Vildagliptin In The Works In India • Source: Shutterstock

More from Business

More from Scrip